Navigation Links
Low-Toxicity, Lipid-Mediated Transfection of Mammalian Cells

Optimizing transfection conditions using LipoTAXI transfection reagent

Peter L. Pingerelli
Stratagene Cloning Systems

Soverin Karmiol
Clonetics Corporation, Walkersville, Maryland

LipoTAXI transfection reagent is a novel liposome reagent that offers low cellular toxicity and high transfection efficiencies for adherent and suspended cells. A procedure is described for optimizing the amounts of LipoTAXI transfection reagent and DNA used to transfect various cell types. Data from the transfection of four human cell strains from the Clonetics Corporation illustrate typical optimization results.

Many facets of gene analysis and recombinant protein expression rely on continuous development and improvement of transfection technology, the procedures for transferring foreign DNA into mammalian cells.1,2 LipoTAXI transfection reagent offers improved, state-of-the-art transfections for diverse cell types and can be used to transfect both adherent cells and cells growing in suspension. Generally, the two most important parameters for achieving optimal transfection efficiencies are the concentration of DNA and the volume of LipoTAXI transfection reagent. By measuring the signal intensity of a reporter gene and the cellular proteins across a matrix of conditions, researchers can easily optimize the amounts of DNA and LipoTAXI transfection reagent for any cell type.

Optimizing Transfection Conditions

The control plasmid provided with LipoTAXI transfection reagent encodes the beta-galactosidase enzyme controlled by the cytomegalovirus (CMV) promoter. Varying amounts of the reporter plasmid were mixed with different volumes of LipoTAXI transfection reagent and added to cells plated in 12-well culture dishes. For these optimization studies, Clonetics Corporation provided the following cell types: small airway epithelial cell s (SAEC), prostate epithelial cells (PrEC), skeletal muscle cells (SkMC) and human mammary epithelial cells (HMEC). Forty-eight hours after transfection of these cell lines, relative expression of the reporter gene was compared3 to determine the optimal concentration of DNA and volume of LipoTAXI transfection reagent. In addition, the amount of protein in each well was measured using a modified Bradford protein reagent to assess the relative cytotoxicity for each set of transfection conditions. Decreasing protein content is an indication of cytotoxicity, whereas high protein content is associated with vigorous cell growth.

figure 1

The tradeoff between higher transfection efficiencies and increasing toxicity is shown in figures 1 and 2. In these experiments, 1 x 105 PrEC cells were plated in 12-well culture dishes and allowed to attach overnight. Reporter plasmid DNA and LipoTAXI transfection reagent were complexed together in serum-free media and then added to the cells. Cells were maintained at 37C in an unhumidified incubator with 5% C02. Signal production from the reporter gene was measured 48 hours following transfection using Stratagenes beta-Galactosidase Assay Kit (figure 1). These data show that an increase in the concentration of DNA results in greater signal production from the reporter gene. As the volume of LipoTAXI transfection reagent varied from 5 to 12.5 l and the amount of DNA varied from 0.5 to 1.5 g, the optimal quantities for each component were revealed. When cells were exposed to higher concentrations of DNA (figure 2), despite an improved signal from the reporter gene, cell protein levels decreased, an indication of incr eased cytotoxicity. Cytotoxic conditions result in cell death, which excludes a subpopulation of cells from transfection studies. In order to ensure a healthy, undamaged cell population and physiologically relevant transfection results, cytotoxic conditions should be avoided.

figure 2

LipoTAXI transfection reagent is consistently gentle to cells, as measured by the final concentration of cell protein per dish, even at high transfection efficiencies. However, the optimal amount of LipoTAXI transfection reagent and DNA varies for each cell line. Table 1 shows such variation in the described cell types.

Cell Type

DNA g

LipoTAXI reagent (l)

SAEC

1.0

5

PrEC

1.5

5

SkMC

1.5

5

HMEC

1.0

10

Table 1

Comparison to Other Commercially Available Transfection Reagents

The optimized amounts of DNA and LipoTAXI transfection reagent as defined in Table 1 were used for comparison to other commercially available transfection reagents. Each transfection reagent was used as recommended by the manufacturer. The best result for each reagent is reported in the graphs (figure 3, panels A, B, C and D).1 These results show LipoTAXI transfection reagent to be consistently effective when used for transfecting this diverse group of noncancerous, human cell lines. In addition, this reagent has been tested and shown to be effective in other cell types (data not shown).

figure 3

Comparison to Other Commercially Available Transfection Reagents

The optimized amounts of DNA and LipoTAXI transfection reagent as defined in Table 1 were used for comparison to other commercially available transfection reagents. Each transfection reagent was used as recommended by the manufacturer. The best result for each r eagent is reported in the graphs (figure 3, panels A, B, C and D).1 These results show LipoTAXI transfection reagent to be consistently effective when used for transfecting this diverse group of noncancerous, human cell lines. In addition, this reagent has been tested and shown to be effective in other cell types (data not shown).

Conclusions

LipoTAXI transfection reagent is a low-toxicity lipid formulation that provides high transfection efficiencies. This reagent consistently yields high transfection efficiencies in a variety of cell types and includes a reporter gene plasmid to be used for easy optimization of transfection conditions. Because LipoTAXI transfection reagent offers low toxicity, the integrity of transfected cells is maintained, yielding physiologically relevant transfection results.

REFERENCE

  1. Ausubel, F.M., et al. (1994) In Current Protocols in Molecular Biology. John Wiley & Sons, New York, NY.

  2. Jordan, M., Schallhorn, A., and Wurn, F.M. (1996) Nucleic Acids Res.24: 596-601.

  3. Eustice, D.C., et al. (1991) Biotechniques 11: 739-743.


'"/>

Source:


Page: All 1 2 3 4 5

Related biology technology :

1. Mycoplasma Contamination Reduces the Effect of Lipid-Mediated Transfection of Mammalian Cells
2. Highest Transfection Efficiency of an Endotoxin-Sensitive Mammalian Cell Line
3. Optimizing Transfection Conditions for Studying Signal Transduction Pathways
4. Transfection of Green Fluorescent Protein into Human Adrenalcarcinoma Cells
5. Improve Lipid- or Calcium Phosphate-Mediated Transfection of Human Dermal Fibroblasts
6. Versatile Transfection Reagent Offers Low Toxicity and Consistent Performance
7. High-Efficiency Transfections Achieved with New Low-Toxicity Reagent
8. Efficient Transfection of Neurospora Crassa
9. Eppendorf Multiporator Transfection Protocols for Eukaryotic Cells
10. Efficient Transfection of Neurospora Crassa
11. Eppendorf Multiporator Transfection Protocols for Eukaryotic Cells
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/27/2016)... ... April 27, 2016 , ... The Pittcon Organizing Committee is pleased to announce ... a volunteer member of Committee since 1987. Since then, he has served in a ... and was chairman for both the program and exposition committees. In his professional career, ...
(Date:4/27/2016)... RESEARCH TRIANGLE PARK, N.C. , April 27, 2016 ... announced today that Martine Rothblatt , Ph.D., Chairman ... an overview and update on the company,s business at ... Conference. The presentation will take place on ... and can be accessed via a live webcast on ...
(Date:4/27/2016)... ... April 27, 2016 , ... PathSensors, Inc., a ... Board. Dr. Lamka will assist PathSensors in expanding the use of the company’s ... the CANARY® test platform for the detection of harmful pathogens, including a number ...
(Date:4/27/2016)... ... 2016 , ... Global Stem Cells Group and the University of ... research and development initiatives for potential stem cell protocol management for 2016 – 2020. ... executives began meeting to establish a working agenda and foster initiatives to promote stem ...
Breaking Biology Technology:
(Date:3/22/2016)... , March 22, 2016 ... research report "Electronic Sensors Market for Consumer Industry by ... & Others), Application (Communication & IT, Entertainment, ... - Global Forecast to 2022", published by ... is expected to reach USD 26.76 Billion ...
(Date:3/17/2016)... -- ABI Research, the leader in transformative technology ... will reach more than $30 billion by 2021, ... electronics, particularly smartphones, continue to boost the biometrics ... two billion shipments by 2021 at a 40% ... Analyst at ABI Research. "Surveillance is also gearing ...
(Date:3/14/2016)... 2016 http://www.apimages.com ) - ... - Renvoi : image disponible via AP Images ... --> DERMALOG, le leader de ... lecteurs d,empreintes digitales pour l,enregistrement des réfugiés en ... pour produire des cartes d,identité aux réfugiés. DERMALOG ...
Breaking Biology News(10 mins):